Skip to main content
. 2015 Sep 18;38(8):311–320. doi: 10.1097/CJI.0000000000000095

FIGURE 4.

FIGURE 4

Tumor protection expressed as the tumor size in CB6F1 mice after 4 injections of phosphate-buffered saline (PBS), recPRAME protein alone, AS15 immunostimulant alone, or recPRAME+AS15, and challenged with CT26-PRAME tumor cells 2 weeks (A) or 2 months (B) after the last injection. Mean tumor sizes at the last time point in each group: (A) recPRAME+AS15, 3.3 mm2; PBS, 218.4 mm2; recPRAME, 154.9 mm2; AS15, 250.5 mm2; (B) recPRAME+AS15, 0.0 mm2; PBS, 218.4 mm2; recPRAME, 96.3 mm2; AS15, 257.1 mm2. Statistically significant differences in mean tumor sizes were observed between groups: (A) recPRAME+AS15 versus AS15, P<0.0001; recPRAME+AS15 versus PBS, P=0.0005; recPRAME+AS15 versus recPRAME, P=0.0010; (B) recPRAME+AS15 versus AS15, P=0.0004; recPRAME+AS15 versus PBS, P<0.0001; recPRAME+AS15 versus recPRAME, P=0.1053. Black arrows represent the injection time points; the last black arrows (in A and B) indicate tumor challenge time points. Data are expressed as the mean tumor size of 8 mice per group. Error bars represent SEs. The numbers of tumor-free mice among the 8 mice included in the analysis per group at the last time point of assessment are indicated. AS15 indicates mice injected with AS15 immunostimulant alone; PBS, mice injected with PBS; recPRAME, mice injected with recombinant PRAME protein alone; recPRAME+AS15, mice injected with recPRAME formulated with AS15 immunostimulant.